– New commitment from the Bill & Melinda Gates Foundation supports the development of Vir’s novel “vaccinal antibody” technology as another important step in the fight to address global infectious ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential ...
– Scientists continuing to advance critical research on mechanisms of immune evasion exemplified by emerging SARS-CoV-2 variants – – Study identifies the N-terminal domain of the SARS-CoV-2 spike ...
VIR-5500 ASCO GU update, VIR-5818 H2’26, ECLIPSE 1 Q4’26 + more hepatitis delta readouts. See more details here.
– New Phase 1 data from PSMA-targeted PRO-XTEN ® dual-masked T-cell engager VIR-5500 in prostate cancer to be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers ...
Vir Biotechnology (NASDAQ:VIR) shares hit a new 52-week low Friday after BofA Securities downgraded its rating of the stock to neutral, citing limited near-term upside. Shares of Vir were down 6% at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results